# US 2025/0145577 A1 · Stereochemically enriched compositions for delivery of nucleic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145577 A1
- Document ID: US20250145577A1
- Status: Published application
- Kind: A1
- Application number: 18/890,983
- Filed: 2024-09-20
- Published: 2025-05-08
- Earliest claimed: 2014-06-24
- Assignees: Translate Bio, Inc.
- Applicants: Translate Bio, Inc.
- Inventors: Frank DeRosa; Shrirang Karve; Michael Heartlein
- Web page: https://patentgrep.com/patent/US20250145577A1

## CPC

- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided, in part, is a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I: a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, the composition characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition: are chemical entities of formula I.a, wherein the first threshold amount is 50%; or are chemical entities of formula I.b.1, wherein the first threshold amount is 25%; or are chemical entities of formula I.b.2, wherein the first threshold amount is 25%, wherein the chemical entities of formula I.a, I.b.1, and I.b.2, are described herein, and methods of using such compositions, for example, for the delivery of a polynucleotide in vivo.

## Claims

### Claim at position 1

1-61. (canceled)

### Claim 62

A composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof,
the composition characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition:
are chemical entities of formula I.a:
wherein the first threshold amount is 50%.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the first threshold amount is
(A) 70%; or
(B) 80%; or
(C) 95%.

### Claim 64 (depends on 62)

The composition of claim 62, wherein greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.a in the composition is a chemical entity of
(i) formula I.a.i:
wherein the second threshold amount is 50%; or
(ii) formula I.a.ii:
wherein the second threshold amount is 50%.

### Claim 65 (depends on 64)

The composition of of claim 64, wherein the second threshold amount is
(a) 70%; or
(b) 80%; or
(c) 90%; or
(d) 95%.

### Claim 66 (depends on 62)

The composition of claim 62, characterized in that greater than or equal to a third threshold amount of the total amount of the composition are chemical entities of formula I.a, wherein the third threshold amount is 85% (w/w).

### Claim 67 (depends on 66)

The composition of claim 66, wherein the third threshold amount is
(a) 90%; or
(b) 95%; or
(c) 98%.

### Claim 68 (depends on 67)

The composition of claim 67, wherein the third threshold amount is 98% and (i) wherein greater than or equal to 90% (w/w) of the total amount of the composition is a chemical entity of formula I.a.i:
(ii) wherein greater than or equal to 90% (w/w) of the total amount of the composition is a chemical entity of formula I.a.ii:

### Claim 69 (depends on 62)

A method of delivery of messenger RNA (mRNA) in vivo, said method comprising administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome wherein said liposome comprises a cationic lipid composition of claim 62, such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo.

### Claim 70 (depends on 69)

The method of claim 69, wherein the liposome further comprises one or more non-cationic lipids, one or more cholesterol-based lipids and/or one or more PEG-modified lipids, optionally wherein the one or more non-cationic lipids are selected from DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DOPC (1,2-dioleyl-sn-glycero-3-phosphotidylcholine) DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)).

### Claim 71 (depends on 70)

The method of claim 70, wherein the one or more cholesterol-based lipids are cholesterol and/or PEGylated cholesterol.

### Claim 72 (depends on 70)

The method of claim 70, wherein the one or more PEG-modified lipids comprise a poly(ethylene) glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C6-C20 length.

### Claim 73 (depends on 69)

The method of claim 69, wherein the liposome has a size less than about 250 nm, 200 nm, 150 nm, 100 nm, 75 nm, or 50 nm.

### Claim 74 (depends on 69)

The method of claim 69, wherein the mRNA has a length of or greater than about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, or 5 kb.

### Claim 75 (depends on 69)

The method of claim 69, wherein
(a) the protein encoded by the mRNA is a cytosolic protein; or
(b) the protein encoded by the mRNA is a secreted protein; or
(c) the protein encoded by the mRNA is an enzyme.

### Claim 76 (depends on 69)

The method of claim 69, wherein the mRNA comprises one or more modified nucleotides; optionally wherein the one or more modified nucleotides comprise pseudouridine, N-1-methyl-pseudouridine, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and/or 2-thiocytidine.

### Claim 77 (depends on 69)

The method of claim 69 wherein the mRNA is unmodified.

### Claim 78 (depends on 69)

The method of claim 69, for treating a disease or disorder comprising a step of delivering an mRNA encoding a therapeutic protein.

### Claim 79

A method for treating a disease or disorder by delivery of an mRNA encoding a therapeutic protein, comprising administering to a subject in need of delivery a pharmaceutical composition comprising a lipid nanoparticle and a pharmaceutically acceptable excipient, wherein the lipid nanoparticle comprises:
a polynucleotide that is messenger RNA (mRNA); one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids;
and one or more chemical entities of formula I, each of which is a compound of formula I:
a pharmaceutically acceptable salt thereof,
characterized in that greater than 50% of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.a.i:

### Claim 80 (depends on 79)

The method of claim 79, wherein the amount of chemical entities of formula I.a.i is greater than:
(a) 70%; or
(b) 80%; or
(c) 90%; or
(d) 95%.

### Claim 81 (depends on 79)

The method of claim 79, wherein the one or more non-cationic lipids are selected from the group consisting of DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DOPC (1,2-dioleyl-sn-glycero-3-phosphotidylcholine) DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), and DOPG (1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)).

### Claim 82 (depends on 79)

The method of claim 79, wherein the one or more cholesterol-based lipids are selected from the group consisting of cholesterol and PEGylated cholesterol.

### Claim 83 (depends on 79)

The method of claim 79, wherein the one or more PEG-modified lipids comprise a poly(ethylene) glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C6-C20 length.

### Claim 84 (depends on 79)

The method of claim 79, wherein the lipid nanoparticle is comprised in a liposome, and wherein the liposome has a size less than 250 nm.

### Claim 85 (depends on 79)

The method of claim 79, wherein the mRNA has a length of or greater than 0.5 kb.

### Claim 86 (depends on 79)

The method of claim 79, wherein the mRNA encodes:
(a) a cytosolic protein; or
(b) a secreted protein; or
(c) an enzyme; or
(d) an intracellular enzyme; or
(e) a transmembrane protein; or
(f) an ion channel protein.

### Claim 87 (depends on 86)

The method of claim 86, wherein the enzyme encoded by the mRNA is an enzyme associated with urea cycle or lysosomal storage metabolic disorders.

### Claim 88 (depends on 79)

The method of claim 79, wherein the mRNA comprises one or more modified nucleotides.

### Claim 89 (depends on 88)

The method of claim 88, wherein the one or more modified nucleotides are selected from the group consisting of pseudouridine, N-1-methyl-pseudouridine, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-methylcytidine, 7-deazaadenosine, 7-deaza-guanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine.

### Claim 90 (depends on 79)

The method of claim 79, wherein the mRNA is unmodified.

### Claim 91 (depends on 79)

A method of manufacture of a medicament for treating a disease or disorder by delivery of a composition comprising an mRNA encoding a therapeutic protein, wherein the mRNA encoding the therapeutic protein is encapsulated within a liposome such that the administration of the composition results in the expression of the protein encoded by the mRNA in the subject; wherein the composition is the pharmaceutical composition of claim 79.
